Marek Hus

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6719719/publications.pdf

Version: 2024-02-01

91	726	623734	642732
papers	citations	14 h-index	23 g-index

94	94	94	1374
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 2022, 11, 752.	4.1	4
2	SARS-CoV-2 Seroprevalence in Healthcare Workers before the Vaccination in Poland: Evolution from the First to the Second Pandemic Outbreak. International Journal of Environmental Research and Public Health, 2022, 19, 2319.	2.6	5
3	Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients. Cancer Management and Research, 2022, Volume 14, 1267-1281.	1.9	0
4	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	1.3	8
5	Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. European Journal of Haematology, 2021, 106, 320-326.	2.2	2
6	Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group. Journal of Clinical Apheresis, 2021, 36, 443-453.	1.3	6
7	In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia. Oncology Letters, 2021, 21, 285.	1.8	4
8	Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma â€“ case series and literature review. Annals of Agricultural and Environmental Medicine, 2021, 29, 103-109.	1.0	0
9	microRNAs as the biomarkers of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. Leukemia and Lymphoma, 2021, 62, 1-9.	1.3	5
10	Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation. Leukemia and Lymphoma, 2021, 62, 3031-3034.	1.3	4
11	Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG). Cancers, 2021, 13, 4189.	3.7	6
12	Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy â€“ a multicenter report by the Polish Myeloma Study Group. Leukemia and Lymphoma, 2021, 62, 3226-3234.	1.3	0
13	Description of invariant NKT cells.. Journal of Education, Health and Sport, 2021, 11, 417-422.	0.1	0
14	RAEB II type of myelodysplastic syndrome associated with axillary abscesses â€“ Case Report. Annals of Agricultural and Environmental Medicine, 2021, 28, 733-736.	1.0	1
15	Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy. Cancers, 2021, 13, 4806.	3.7	5
16	An epileptic seizure and haemorrhage into the ventricular system of the brain as the first manifestations of acquired haemophilia A â€“ Case report. Annals of Agricultural and Environmental Medicine, 2021, 28, 531-533.	1.0	0
17	Chemotherapy-Related Differences in Cognitive Functioning and Their Biological Predictors in Patients with Multiple Myeloma. Brain Sciences, 2021, 11, 1166.	2.3	5
18	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). Leukemia and Lymphoma, 2020, 61, 588-603.	1.3	1

#	Article	IF	Citations
19	A Case Report of a Female Patient With Hodgkin Lymphoma Localized in the Central Nervous System and With Concomitant Pulmonary Lymphomatoid Granulomatosis. Frontiers in Neurology, 2020, 11, 963.	2.4	1
20	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. Anticancer Research, 2020, 40, 4059-4066.	1.1	8
21	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. Advances in Medical Sciences, 2020, 65, 371-377.	2.1	2
22	Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma. Anticancer Research, 2020, 40, 5437-5443.	1.1	2
23	Cofilin-1 Maintains Prosurvival Signaling in Chronic Lymphocytic Leukemia Cells. Anticancer Research, 2020, 40, 6327-6335.	1.1	0
24	Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia . Cancer Management and Research, 2020, Volume 12, 9977-9985.	1.9	8
25	Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. Annals of Hematology, 2020, 99, 2881-2891.	1.8	18
26	Serum brainâ€derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. British Journal of Haematology, 2020, 191, 77-89.	2.5	16
27	The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma. BioMed Research International, 2020, 2020, 1-15.	1.9	9
28	Infectious Complications in Patients With Multiple Myeloma After High-Dose Chemotherapy Followed by Autologous Stem Cell Transplant: Nationwide Study of the Infectious Complications Study Group of the Polish Adult Leukemia Group. Transplantation Proceedings, 2020, 52, 2178-2185.	0.6	12
29	Differentiation of metastatic lesions to the bones and multiple myeloma â€“ a case study. Journal of Education, Health and Sport, 2020, 10, 28.	0.1	0
30	Rare case of Richterâ€™s syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) â€“ Case report and literature. Annals of Agricultural and Environmental Medicine, 2020, 27, 160-164.	1.0	0
31	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients â‰¥ 60 Years Old (PALG-AML1/2016). Blood, 2020, 136, 3-4.	1.4	0
32	Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. Annals of Hematology, 2019, 98, 2197-2211.	1.8	25
33	The Association of GSTT1, GSTM1, and TNF-Î± Polymorphisms With the Risk and Outcome in Multiple Myeloma. Frontiers in Oncology, 2019, 9, 1056.	2.8	20
34	Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients . Cancer Management and Research, 2019, Volume 11, 5021-5031.	1.9	6
35	Polymorphisms in the promotor region of the <scp>CRBN</scp> gene as a predictive factor for peripheral neuropathy in the course of thalidomideâ€based chemotherapy in multiple myeloma patients. British Journal of Haematology, 2019, 186, 695-705.	2.5	7
36	ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma. Frontiers in Oncology, 2019, 9, 44.	2.8	24

#	Article	IF	Citations
37	TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 55-65.	2.3	5
38	Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group. Blood, 2019, 134, 5276-5276.	1.4	1
39	Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in acompassionate use program: A report from the Polish Adult Leukemia Study Group (PALG). Advances in Clinical and Experimental Medicine, 2019, 28, 1051-1057.	1.4	7
40	The role of immune checkpoint inhibitors inÂprostate cancer. Annals of Agricultural and Environmental Medicine, 2019, 26, 120-124.	1.0	3
41	Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. Blood, 2019, 134, 5456-5456.	1.4	0
42	Intracellular ILâ€‘4 and IFNâ€Î³ expression in iNKT cells from patients with chronic lymphocytic leukemia. Oncology Letters, 2018, 15, 1580-1590.	1.8	12
43	Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of <scp>CLL</scp> patients; the Polish Adult Leukemia Group report (<scp>PALG</scp>). European Journal of Haematology, 2018, 100, 389-391.	2.2	7
44	Intraventricular treatment of secondary central nervous system lymphoma â€“ Case study and literature overview. Neurologia I Neurochirurgia Polska, 2018, 52, 410-414.	1.2	1
45	Central nervous involvement by chronic lymphocytic leukaemia. Neurologia I Neurochirurgia Polska, 2018, 52, 228-234.	1.2	3
46	Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin â€“ Prelimary results. Annals of Agricultural and Environmental Medicine, 2018, 25, 56-59.	1.0	3
47	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study. Blood, 2018, 132, 1960-1960.	1.4	1
48	Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma. Advances in Clinical and Experimental Medicine, 2018, 27, 1683-1689.	1.4	4
49	Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease. Oncotarget, 2018, 9, 19136-19146.	1.8	5
50	Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. Oncotarget, 2018, 9, 24054-24068.	1.8	6
51	TP53 polymorphism in plasma cell myeloma. Folia Histochemica Et Cytobiologica, 2018, 55, 203-211.	1.5	3
52	Analysis of Risk Factors Determining Incidence and Outcome of Infections in Children and Adults after Hematopoietic Cell Transplantation. Blood, 2018, 132, 3364-3364.	1.4	0
53	Skuteczne leczenie ibrutynibem chorego na przewlekÅ‚Ä… biaÅ‚aczkÄ… limfocytowÄ… z obecnoÅ›ciÄ… delecji 17p â€“ opis przypadku. Acta Haematologica Polonica, 2018, 49, 251-256.	0.3	0
54	Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leukemia and Lymphoma, 2017, 58, 2089-2100.	1.3	12

#	Article	IF	Citations
55	Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). Leukemia and Lymphoma, 2017, 58, 2485-2488.	1.3	34
56	Analiza skutecznoÅ›ci ibrutynibu w podgrupie chorych na przewlekÅ‚Ä… biaÅ‚aczkÄ™ limfocytowÄ… z delecjÄ… 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia BiaÅ‚aczek u DorosÅ‚ych (PALG). Acta Haematologica Polonica, 2017, 48, 330-337.	0.3	1
57	Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. Oncotarget, 2017, 8, 34661-34669.	1.8	28
58	Diagnosis and treatment options of acquired hemophilia - a single center experience. Polish Archives of Internal Medicine, 2017, 127, 796-799.	0.4	2
59	SkutecznoÅ›Ä‡ i bezpieczeÅ„stwo stosowania nilotynibu w leczeniu przewlekÅ‚ej biaÅ‚aczki szpikowej wspÃ³Å‚istniejÄ…cej z cukrzycÄ… typu 2. Hematologia, 2017, 8, 11-13.	0.0	0
60	Specific cytotoxic Tâ€cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells. British Journal of Haematology, 2016, 174, 582-590.	2.5	3
61	Profile of serum biomarkers in eosinophilic disorders. European Journal of Internal Medicine, 2016, 29, e19-e20.	2.2	0
62	Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia. Annals of Hematology, 2016, 95, 425-435.	1.8	7
63	Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Leukemia and Lymphoma, 2016, 57, 708-710.	1.3	9
64	Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 32846-32853.	1.8	44
65	New prognostic biomarkers in multiple myeloma. Postepy Higieny I Medycyny Doswiadczalnej, 2016, 70, 811-819.	0.1	5
66	Advances in hematology â€“ research that revolutionized patient care. Zdrowie Publiczne, 2015, 125, 32-35.	0.1	0
67	Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor. Pharmacological Reports, 2015, 67, 1193-1200.	3.3	3
68	The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. European Journal of Clinical Pharmacology, 2015, 71, 1121-1127.	1.9	2
69	Therapyâ€related peripheral neuropathy in multiple myeloma patients. Hematological Oncology, 2015, 33, 113-119.	1.7	63
70	Optimizing the Treatment of Patients WithÂMultiple Myeloma and Renal Impairment. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 187-198.	0.4	20
71	Cytotoxic Activity of Valproic Acid on Primary Chronic Lymphocytic Leukemia Cells. Advances in Clinical and Experimental Medicine, 2015, 24, 55-62.	1.4	6
72	Cardiovascular dysfunction as a common cause of mortality in hypereosinophilic syndromes. Polish Archives of Internal Medicine, 2015, 125, 692-694.	0.4	1

#	Article	IF	Citations
73	Review New drugs in multiple myeloma â€“ role of carfilzomib and pomalidomide. Wspolczesna Onkologia, 2014, 1, 17-21.	1.4	3
74	Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance. Medical Oncology, 2014, 31, 815.	2.5	16
75	Oral mucositis in patients with leukaemia following high-dose chemotherapy and autologous haematopoietic stem cells transplantation. Acta Haematologica Polonica, 2014, 45, 258-263.	0.3	1
76	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematological Oncology, 2013, 31, 41-48.	1.7	39
77	Minimally invasive, endovenous laser treatment of varicose veins in patients with von Willebrand disease. Annals of Agricultural and Environmental Medicine, 2013, 20, 880-3.	1.0	0
78	1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leukemia and Lymphoma, 2012, 53, 2500-2503.	1.3	10
79	Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRÎ±-negative hypereosinophilic syndrome. Medical Oncology, 2012, 29, 1073-1076.	2.5	22
80	Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Annals of Hematology, 2011, 90, 1161-1166.	1.8	46
81	Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRÎ±-positive chronic eosinophilic leukaemia. Cancer Chemotherapy and Pharmacology, 2011, 67, 967-969.	2.3	24
82	Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib. Leukemia Research, 2011, 35, e15-e17.	0.8	2
83	Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens. Blood, 2011, 118, 2874-2874.	1.4	1
84	Treatment of multiple myeloma patients with autologous stem cell transplantation — a fresh analysis. Folia Histochemica Et Cytobiologica, 2011, 49, 248-254.	1.5	2
85	Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1â€PDGFRA fusion transcriptâ€"results of Polish multicentre study. Hematological Oncology, 2010, 28, 93-97.	1.7	19
86	Heterogeneity among characteristics of hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology, 2010, 125, 1399-1401.e2.	2.9	10
87	Long-Term Remission Maintenance on Weekly Imatinib Dosage In Patients with FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukaemia. Blood, 2010, 116, 4097-4097.	1.4	0
88	Acute T Cell Lymphoblastic Leukemia in the Recipient of a Renal Transplant from a Donor with Malignant Lymphoma. Acta Haematologica, 2008, 119, 187-189.	1.4	3
89	Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. Haematologica, 2006, 91, 386-9.	3.5	7
90	Stimulation of Erythropoiesis by Thalidomide in Multiple Myeloma Patients: Its Influence on FasL, TRAIL and Their Receptors on Erythroblasts and Plasma Cells.. Blood, 2005, 106, 5120-5120.	1.4	0

#	Article	IF	Citations
91	Production of Proangiogenic Cytokines During Thalidomide Treatment of Multiple Myeloma. Leukemia and Lymphoma, 2002, 43, 401-406.	1.3	6